Abstracts tagged "gout"

Abstract Number: 1181 • 2013 ACR/ARHP Annual Meeting
The Effect Of Uric Acid Lowering Therapy In Preventing Comorbidity and Acute Attack Of Gout; A Retrospective Study
Kowoon Joo¹, Won Park¹, Seong-Ryul Kwon¹, Mie-Jin Lim¹, Kyong-Hee Jung¹, Hoyeon Joo¹ and Sung-Soo Kim², ¹Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Ulsan Univ College of Medicine and Gangneung Asan Hospital, Gangneung, South Korea
Background/Purpose: We evaluated the effect of uric acid lowering therapy (ULT) in reducing the new development of comorbidities and the frequency of acute attacks…
Abstract Number: 212 • 2013 ACR/ARHP Annual Meeting
Dual-Energy Computed Tomography for Monitoring of Urate Deposition in Tophaceous Gout: A Prospective Longitudinal Study Examining Sensitivity to Change
Ashwin Rajan¹, Opetaia Aati², Ramanamma Kalluru³, Gregory Gamble², Anne Horne², Anthony Doyle¹, Fiona M. McQueen⁴ and Nicola Dalbeth⁵, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁴Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ⁵Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Dual-energy computed tomography (DECT) is an advanced imaging method with potential for monitoring urate deposition in patients with gout. The aim of this prospective…
Abstract Number: 1996 • 2013 ACR/ARHP Annual Meeting
Racial/Ethnicity Differences In Health-Related Quality Of Life (HRQOL), Functional Ability and Health Care Utilization In Gout Patients
Aseem Bharat¹, Jasvinder A. Singh^2,3, Puja Khanna⁴, Cleopatra Aquino-Beaton⁵, Jay E. Persselin⁶, Erin Duffy⁷, David Elashoff⁸ and Dinesh Khanna⁹, ¹Medicine/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, Birmingham VA, Birmingham, AL, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁶Medicine W-111J Div of Rheum, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁷Medicine, University of California Los Angeles, Los Angeles, CA, ⁸Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: Due to limited/no data for race/ethnicity, our objective was to assess whether HRQOL functional ability and health care utilization in gout patients differs by…
Abstract Number: 1183 • 2013 ACR/ARHP Annual Meeting
The Treatment Of Gout In Relation To The 2012 Uric Acid Target Guidelines In The US Population
Stephen Juraschek¹, Lara Kovell², Edgar Miller III² and Allan C. Gelber³, ¹Department of Medicine, Johns Hopkins University, Baltimore, MD, ²Medicine, Johns Hopkins University, Baltimore, MD, ³Medicine/ Rheumatology, Johns Hopkins University, Baltimore, MD
The Treatment of Gout in Relation to the 2012 Uric Acid Target Guidelines in the US Population Background/Purpose: Gout is a debilitating form of arthritis mediated…
Abstract Number: 213 • 2013 ACR/ARHP Annual Meeting
Digital Tomosynthesis for Measurement of Bone Erosion in Gout: Comparison With Computed Tomography
Nicola Dalbeth¹, Anthony Doyle², Mark Roger³, Angela Gao⁴ and Fiona M. McQueen⁵, ¹Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Department of Radiology, Auckland District Health Board, Auckland, New Zealand, ⁴Radiology, Auckland District Health Board, Auckland, New Zealand, ⁵Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
Background/Purpose: Digital tomosynthesis is a recently developed imaging method in which multiple projected images obtained at different angles are collected with a digital detector. These…
Abstract Number: 2001 • 2013 ACR/ARHP Annual Meeting
Kaiser Permanent Pyramid In Patients With Gout: The Most Severe Gout Is Associated To The Most Complex Patients
Fernando Perez-Ruiz^1,2, Ana M. Herrero-Beites^1,3 and Amaya Martinez-Galarza^4,5, ¹BioCruces Health Research Institute, Baracaldo, Spain, ²Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ³Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain, ⁴Clinical Investigation Unit, Hospital Universitario Cruces, Baracaldo, Spain, ⁵BioCruces Health Institute, Baracaldo, Spain
Background/Purpose: gout is well known to be associated with comorbid conditions; the Kaiser Permanente Pyramid (KPP) identify high risk people (two higher strata) in the…
Abstract Number: 1184 • 2013 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Plays a Role In Gouty Arthritis
Kiwon Moon¹, Jinhyun Kim² and Yun Jong Lee³, ¹Internal medicine,, Kangwon National University Hospital, Chuncheon city, Kangwon province, South Korea, ²Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ³Division of Rheumatology, Department of Internal Medicine,Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: High mobility group box 1 (HMGB1) is a crucial cytokine that mediated the response to infection, injury and inflammation. It is recently discovered that…
Abstract Number: 180 • 2013 ACR/ARHP Annual Meeting
Familial Aggregation Of Female Premenopausal Gout –Monogenic, Polygenic Or Clinical Coincidence?
Bingqing Zhang¹, Shufen Liu², Nuo Si³, Yun Zhang^2,4 and Xuejun Zeng⁵, ¹Peking Union Medical College, Beijing, China, ²Peking Union Medical College Hospital, Beijing, China, ³Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁵Medicine, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Primary gout is a multifactorial disease, in which genetic background and environmental factors interact with each other. Genetic predisposition is particularly prominent in those…
Abstract Number: 2007 • 2013 ACR/ARHP Annual Meeting
Using Natural Language Processing and Machine Learning To Identify Gout Flares From Electronic Clinical Notes
Chengyi Zheng¹, Nazia Rashid², T. Craig Cheetham³, Yi-Lin Wu³ and Gerald D. Levy⁴, ¹Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ²Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA, ³Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, ⁴Int Med/Rheumatology, Southern California Permanente Medical Group, Downey, CA
Background/Purpose: Gout flares are the most common manifestation of gout. Gout flares are not well documented by diagnosis codes and are not adequately captured when…
Abstract Number: 1185 • 2013 ACR/ARHP Annual Meeting
More Than One-Third Of Patients Reach Serum Urate Target and Continue To Report Multiple Flares
Dinesh Khanna¹, Puja Khanna², Chris Storgard³, Scott Baumgartner⁴ and Robert Morlock⁵, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Biosciences, San Diego, CA, ⁵Ardea Bioscience, San Diego, CA
Background/Purpose: Gout is a common inflammatory arthritis, and its worldwide prevalence is increasing. EULAR and ACR guidelines recommend a target serum urate (sUA) ≤6 mg/dL.…
Abstract Number: 1984 • 2013 ACR/ARHP Annual Meeting
Impact Of Educational Attainment On Health-Related Quality Of Life and Healthcare Utilization Among Veterans With Gout
Cleopatra Aquino-Beaton¹, Jay E. Persselin², Ari Weinreb¹, Meika A Fang¹, Jasvinder A. Singh^3,4, Erin Duffy⁵, David Elashoff⁶, Puja Khanna^7,8 and Dinesh Khanna⁹, ¹Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ²Medicine W-111J Div of Rheum, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Rheumatology, Birmingham VA, Birmingham, AL, ⁵Medicine, University of California Los Angeles, Los Angeles, CA, ⁶Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁷Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁸Rheumatology, Ann Arbor VA, Ann Arbor, MI, ⁹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Gout is a debilitating, chronic disease that requires ongoing treatment and effective self-management. Successful gout treatment depends on multiple factors, including educational attainment. Adequate…
Abstract Number: 1186 • 2013 ACR/ARHP Annual Meeting
Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries
Jasvinder A. Singh¹, Chris Storgard², Scott Baumgartner³ and Robert Morlock⁴, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²4939 Directors Place, Ardea Bioscience, San Diego, CA, ³Ardea Biosciences, San Diego, CA, ⁴Ardea Bioscience, San Diego, CA
Background/Purpose: Allopurinol is the most commonly used urate-lowering therapy (ULT) in the world. Although allopurinol is FDA approved for up to 800 mg/d and EMEA…
Abstract Number: 1987 • 2013 ACR/ARHP Annual Meeting
LIVER Outcomes In Gout Patients Treated With Febuxostat and Altered LIVER Function TESTS
Fernando Perez-Ruiz^1,2 and Ana M. Herrero-Beites^2,3, ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²BioCruces Health Research Institute, Baracaldo, Spain, ³Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
LIVER OUTCOMES IN GOUT PATIENTS TREATED WITH FEBUXOSTAT AND ALTERED LIVER FUNCTION TESTSBackground/Purpose: patients with significantly altered liver function test (LFTs) at screening do not…
Abstract Number: 1187 • 2013 ACR/ARHP Annual Meeting
A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout
Michael A. Becker¹, David Fitz-Patrick², Chris Storgard³, Matt Cravets⁴ and Scott Baumgartner⁵, ¹Medicine, University of Chicago, Chicago, IL, ²East-West Medical Research Institute, Honolulu, HI, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Ardea Biosciences, San Diego, CA
Background/Purpose: Documentation of the safety profile of allopurinol at doses ≥300 mg/day is important for its ongoing use as first-line monotherapy or in combination with…
Abstract Number: 1988 • 2013 ACR/ARHP Annual Meeting
Self-Reported Gout, Comorbidities and Healthcare Resource Utilization Data From The 2012 United States National Health and Wellness Survey
Jasvinder A. Singh¹, Kathy Annunziata² and Puja Khanna³, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²Kantar Health, Princeton, NJ, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Hyperuricemia and gout are associated with major cardiovascular and metabolic comorbidities. Recently published data on comorbidities and gout epidemiology in the US have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].